Subscribe: pubmed: 0732-8893
http://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=08MvN2nSI1hWgLCEFGwN8BYEaG5H0-UdoicKXBQVpHB
Preview: pubmed: 0732-8893

pubmed: 0732-8893



NCBI: db=pubmed; Term=0732-8893



 



Comparison of 4 commercially available group B Streptococcus molecular assays using remnant rectal-vaginal enrichment broths.
Related Articles

Comparison of 4 commercially available group B Streptococcus molecular assays using remnant rectal-vaginal enrichment broths.

Diagn Microbiol Infect Dis. 2018 Mar 28;:

Authors: Relich RF, Buckner RJ, Emery CL, Davis TE

Abstract
The incidence of neonatal Group B streptococcal (GBS) disease has significantly declined since the widespread implementation of prenatal screening of expectant mothers for urogenital and gastrointestinal tract GBS colonization. Screening methods have evolved from exclusively culture-based approaches to more rapid and highly sensitive molecular methods. We chose to evaluate the performance of 4 commercially available GBS molecular tests for detection of GBS colonization using 299 antepartum rectal-vaginal specimens submitted to our laboratory for routine GBS screening. In 97% of instances, there was agreement between all 3 systems. When testing 1, 6, and 12 samples simultaneously, all methods performed comparably, but the ARIES® GBS assay required the least total hands-on time and the illumigene® Group B Streptococcus assay required the most hands-on time.

PMID: 29685609 [PubMed - as supplied by publisher]